Gardiner Harris accuses Johnson & Johnson of lethal marketing and corruption. His book links major products to millions of deaths and a Spanish health scandal, while available sources do not independently confirm the estimate of two million deaths.
Gardiner Harris estimates that Johnson & Johnson’s conduct caused the deaths of around two million Americans through three products alone.
His new book accuses the company of turning repeated health scandals into a system for protecting sales and its reputation. The investigation also links the multinational to concealed information about erythropoietin, EPO, and cancer in Spain. The available research reviewed for this article does not independently confirm the estimate. Testing it would require a separate examination of the methodology and underlying data, including its epidemiological basis.
The allegations appear in 'No llores más: Los oscuros secretos de Johnson & Johnson', published by Capitán Swing in 2026. Harris argues that the company combined illegal marketing with negligence and relied on an army of lawyers while the US Food and Drug Administration, FDA, gradually lost independence.
In a settlement of approximately $2 billion, Janssen agreed to plead guilty to one criminal violation of the Food, Drug, and Cosmetic Act connected with the promotion of Risperdal. The agreement also covered investigations involving Invega and Natrecor and claims brought by 45 states and federal authorities.
The book’s central charge is the gap between Johnson & Johnson’s trusted image and the conduct Harris describes. Official enforcement records support part of that broader picture. The US Department of Justice has documented criminal and civil allegations concerning the marketing of medicines, while other claims remain disputed or unresolved.
In an interview with ABC, the veteran journalist said the project brought threats, editorial blockages in several countries and intensive legal scrutiny. Those obstacles cut the original manuscript by half. The final work runs to more than 500 pages.
Harris has covered the pharmaceutical industry for The New York Times and The Wall Street Journal. His account follows the products that defined different periods of American life. Talcum powder belonged to the baby boom, while painkiller Tylenol became another focus. The book also examines early antipsychotics and fentanyl.
In 2023, Johnson & Johnson proposed transferring $8.9 billion to its subsidiary LTL Management to fund talc claims over 25 years. The company did not admit liability and continued to describe the allegations as scientifically unfounded; the proposal did not automatically resolve the litigation.
For Harris, that commercial succession is also a history of corporate crisis management. Each blockbuster product became a cultural symbol, and each scandal supplied lessons that could contain the next one. He describes US healthcare as simultaneously the world’s best and worst system because its scientific capacity coexists with extensive corruption.
One mechanism he highlights is the payment of doctors to work as part-time sales representatives. That claim puts medical influence at the centre of Johnson & Johnson’s business model instead of treating the scandals as isolated failures.
The opioid litigation offers a documented measure of the controversy. Johnson & Johnson agreed to contribute approximately $5 billion to a nationwide settlement over its role in opioid marketing and stopped national sales of opioid painkillers. The broader framework involving distributors was valued at about $26 billion and covered more than 3,000 lawsuits brought by states and municipalities.
The Spanish connection is especially serious in Harris’s account. He says Johnson & Johnson withheld information about EPO and cancer for more than a decade and estimates that the concealment caused thousands of deaths. The book also covers hip implants and vaginal meshes as further cases beyond the three products included in his estimate of two million American deaths. Those mortality figures must be separated from the documented existence of litigation and regulatory investigations. The sources reviewed here do not verify the book’s aggregate estimate.
The investigation’s publication difficulties form part of the story. Harris says concerns about defamation lawsuits delayed or obstructed release in several countries. He also dates the FDA’s gradual decline to 1992, when pharmaceutical companies began providing most of the agency’s funding.
That funding shift matters because the regulator was created to police the industry whose money increasingly supported it. Harris’s case therefore reaches beyond one company. He describes a health system in which legal resources and commercial influence can outlast public scrutiny.
The material in the book does not describe a single product failure. It presents a recurring pattern involving blockbuster medicines and consumer products, followed by allegations of concealment, illegal promotion and institutional dependence. That pattern puts Johnson & Johnson’s carefully built public image under direct scrutiny. Harris treats corporate trust as an outcome of accountability rather than advertising.
The talc disputes show why the company’s public image remains contested rather than settled by one court result. Johnson & Johnson maintains that its talc did not cause cancer and did not contain asbestos. Yet it stopped selling talc-based baby powder in the United States and Canada in 2020, then worldwide in 2023, switching to cornstarch.
Federal litigation in New Jersey still involved tens of thousands of claims concerning ovarian cancer and mesothelioma. A proposed 2026 settlement of roughly $5.5 billion reportedly covers about 76,000 claims, but it depends on participation by at least 95% of claimants. It therefore should not be presented as an automatically final resolution.
The legal record does not establish a single uncontested scientific conclusion about talc. In one recent proceeding, a federal court rejected Johnson & Johnson’s claim against three scientists who had published research on a possible link between cosmetic talc and mesothelioma. The court found insufficient evidence that they knowingly or recklessly published false data.
Johnson & Johnson continues to deny the allegations, while that ruling addressed whether the scientists knowingly or recklessly published false data.
